Edgar Filing: NAVIDEA BIOPHARMACEUTICALS, INC. - Form 8-K

NAVIDEA BIOPHARMACEUTICALS, INC. Form 8-K March 13, 2017 **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K **CURRENT REPORT** PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) March 8, 2017 NAVIDEA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35076 31-1080091 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 5600 Blazer Parkway, Suite 200, Dublin, Ohio 43017 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code (614) 793-7500

(Former name or former address, if changed since last report.)

Edgar Filing: NAVIDEA BIOPHARMACEUTICALS, INC. - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[&]quot;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[&]quot;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[&]quot;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[&]quot;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
5.02 Compensatory Arrangements of Certain Officers.

On March 8, 2017, Thomas J. Klima resigned as Senior Vice President and Chief Commercial Officer of Navidea Biopharmaceuticals, Inc. to pursue other opportunities.

Edgar Filing: NAVIDEA BIOPHARMACEUTICALS, INC. - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Navidea Biopharmaceuticals, Inc.

Date: March 13, 2017 By: /s/ Jed A. Latkin

Jed A. Latkin, Interim Chief Operating Officer